Key result
ARNI, beta-blockers, MRAs, and SGLT2 inhibitors form the four mortality-reducing pillars of HFrEF therapy.
Why the study?
To evaluate, describe and compare the pharmacological treatments available for heart failure.
Design
Literature review
Authors
Loading...
Reinforces four-pillar HFrEF therapy as current standard; leaves open optimal implementation and access questions for prospective study.
This review summarizes the current pharmacological management of chronic heart failure, emphasizing the four pillars of HFrEF therapy: ARNI, beta-blockers, MRAs, and SGLT2 inhibitors.
Pinto et al. (2022) conducted a review in Chronic heart failure. Pharmacotherapy (ANRi, beta-blockers, MRA, SGLT2i) was evaluated. Current mortality-reducing pharmacotherapy for heart failure with reduced ejection fraction relies on four main drug classes: ANRi, beta-blockers, MRA, and SGLT2 inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: